Your Sorted CME/CE Activities

Hot Topics on Relapsed/Refractory Multiple Myeloma from the 63rd ASH Annual Meeting*
Certified AMA Activity - Clinical Clips

The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients. 

This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Review the video to claim AMA credit after completion of the brief Post-Test/Evaluation.
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, MEd, FRCPC
Professor, Applied Cancer Research
and Drug Discovery, Translational
Genomics Research Institute (TGen)
City of Hope Cancer Center
Chief Medical Officer, International
Myeloma Foundation
Consultant Hematologist
and Director, Myeloma Research
Phase 1 Program
HonorHealth Research Institute
Adjunct Professor, College of Health
Solutions, Arizona State University






*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2021 American Society of Hematology Annual Meeting (ASH)
20
Supported by an independent educational grant from Bristol Myers Squibb

Launch Date: December 18, 2021
Release Date: December 18, 2021
Expiration Date: November 30, 2022

November 30, 2022
Mini Module
7288
ClinicalClips_WebBanner.ASH.MultipleMyeloma(1150).gif
Hem-Onc